用于根除HIV的广泛中和抗体。
Broadly Neutralizing Antibodies for HIV Eradication.
作者信息
Stephenson Kathryn E, Barouch Dan H
机构信息
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, E/CLS-1043, 330 Brookline Avenue, Boston, MA, 02215, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, MA, USA.
出版信息
Curr HIV/AIDS Rep. 2016 Feb;13(1):31-7. doi: 10.1007/s11904-016-0299-7.
Passive transfer of antibodies has long been considered a potential treatment modality for infectious diseases, including HIV. Early efforts to use antibodies to suppress HIV replication, however, were largely unsuccessful, as the antibodies that were studied neutralized only a relatively narrow spectrum of viral strains and were not very potent. Recent advances have led to the discovery of a large portfolio of human monoclonal antibodies that are broadly neutralizing across many HIV-1 subtypes and are also substantially more potent. These antibodies target multiple different epitopes on the HIV envelope, thus allowing for the development of antibody combinations. In this review, we discuss the application of broadly neutralizing antibodies (bNAbs) for HIV treatment and HIV eradication strategies. We highlight bNAbs that target key epitopes, such as the CD4 binding site and the V2/V3-glycan-dependent sites, and we discuss several bNAbs that are currently in the clinical development pipeline.
长期以来，抗体的被动转移一直被视为包括艾滋病病毒（HIV）在内的传染病的一种潜在治疗方式。然而，早期利用抗体抑制HIV复制的努力大多未成功，因为所研究的抗体仅能中和相对较窄范围的病毒株，且效力不强。最近的进展促使人们发现了大量人类单克隆抗体，这些抗体能广泛中和多种HIV-1亚型，且效力也显著更强。这些抗体靶向HIV包膜上的多个不同表位，从而使得抗体组合的研发成为可能。在本综述中，我们讨论了广泛中和抗体（bNAbs）在HIV治疗和HIV根除策略中的应用。我们重点介绍了靶向关键表位（如CD4结合位点和V2/V3聚糖依赖性位点）的bNAbs，并讨论了目前正处于临床开发阶段的几种bNAbs。
Zotero 插件